GET DAILY SIGNALSCompugen (CGEN) Stock: Path to +116% Upside Hinges on Key 2027 Catalysts
Key Takeaways
- The central stock price target used here is $4.60, the arithmetic mean of five verified analyst price targets, spanning roughly $4.00 to $6.00.
- At a latest price near $2.13, reaching $4.60 would require roughly 116% upside — a very large move for a clinical-stage biotech.
- The bull case rests on 2027 clinical catalysts, including the MAIA-Ovarian readout for COM701 and AstraZeneca's Phase 3 rilvegostomig data, plus a cash runway into 2029.
- The main risks are a small, exploratory COM701 trial not powered for statistical significance, and reported revenue that largely reflects accounting recognition of partner payments rather than new demand.
- All five tracked analysts rate the stock a Buy or Outperform, but targets cluster tightly, signaling limited confidence beyond a binary data event.
- Readers can explore more on Compugen's Major News, Today's Price Move, Forecast, and Earnings pages.
- For additional data-driven ideas, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Compugen Ltd. (CGEN) is a clinical-stage immuno-oncology company headquartered in Holon, Israel, listed on the Nasdaq and the Tel Aviv Stock Exchange. Its shares carry a "Strong Buy" consensus among the analysts tracked, but coverage is thin and targets are tightly grouped. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Five verifiable targets were reviewed: H.C. Wainwright at $4.00 (reiterated October 12, 2026), Stifel at $4.00, Lake Street at $6.00 (initiated April 7, 2026), Leerink Partners at $5.00 (lowered from $13.00 on May 21, 2026), and a further $4.00 target. This produces an approximate range of $4.00 to $6.00 and an average analyst price target of $4.60. The figure is a calculation of the individual targets, not an official published consensus; some data providers round the average to $5.00.
All five analysts sit on the constructive side, but the narrow spread reflects a shared view that Compugen's value is anchored to discrete clinical events rather than near-term fundamentals. Leerink's sharp cut from $13 to $5 in mid-2026 illustrates how quickly expectations can recalibrate for a pre-revenue biotech.
Current Market Position and Path Toward the Target
The stock closed near $2.13 after reporting third-quarter 2026 results, having traded as low as roughly $1.87 days earlier and near $2.94 in late August. Moving to $4.60 would require about 116% upside — a very large move that would depend on re-rating the shares around data catalysts rather than earnings growth.
For the third quarter, Compugen reported a net loss of $0.06 per share, beating a roughly $0.08 estimate, on revenue of about $3.8 million versus roughly $1.9 million a year earlier. The company held approximately $117.5 million in cash and investments as of September 30, 2026, with management guiding to a runway into 2029. The path to $4.60, however, runs primarily through a binary clinical readout expected by the end of the first quarter of 2027.
What Could Support a Move Toward the Target
The central catalyst is COM701, a potential first-in-class anti-PVRIG antibody being evaluated in the fully enrolled MAIA-Ovarian trial (62 patients randomized 2:1 against placebo). A credible efficacy signal could transform how investors value the wholly owned asset.
Partner programs provide additional optionality. Rilvegostomig, a PD-1/TIGIT bispecific antibody, is being advanced by AstraZeneca (AZN) across 12 Phase 3 trials, with high-level results from ARTEMIDE-Biliary01 now expected in the second half of 2027. Compugen is eligible for up to $195 million in milestones plus mid-single-digit royalties. Separately, Gilead (GILD) is advancing GS-0321, an anti-IL-18 binding protein antibody, under a deal worth up to $758 million in additional milestones plus royalties. A strengthened cash runway into 2029 reduces near-term financing risk.
What Could Prevent the Target From Being Reached
The MAIA-Ovarian study is exploratory and not powered for statistical significance, so even a favorable readout may not establish an approval-ready package. Management's framing of success has shifted toward the "totality of the data," which leaves room for an ambiguous result.
Third-quarter revenue consisted largely of recognizing portions of Gilead's upfront and IND milestone payments — non-cash accounting recognition rather than new demand. A significant share of Compugen's potential value depends on partner execution, and the next AstraZeneca milestone is tied to BLA (Biologics License Application) acceptance, meaning a positive trial alone would not trigger payment. Emerging antibody-drug conjugate competition in ovarian maintenance adds further uncertainty.
Technical Levels and Market Structure
After the August report, shares rallied toward roughly $2.94 before giving back the entire move. The stock has traded near a recent low around $1.87 and, entering November, sat roughly 14% below its $2.29 200-day moving average. A sustained move above that average and the low-$3.00 area would be a notable structural shift, while the $4.00–$6.00 target band sits well above any recent resistance zone, underscoring how much the thesis depends on clinical data rather than technical repair.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may differ and no specific horizon was stated for all five. Investors should watch the MAIA-Ovarian data expected by the end of the first quarter of 2027, the rilvegostomig Phase 3 readout anticipated in the second half of 2027, any GS-0321 data disclosures (which require Gilead's cooperation), cash burn, and any analyst target revisions around these events.
Using AI Daily Buy/Sell Signals in My Research
AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a binary, catalyst-heavy name like Compugen, such tools can help traders track shifts in momentum and sentiment without manually screening charts. Traders can use the signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently. I find them a useful input within a broader research process, especially when preparing for binary events like upcoming readouts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CGEN's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CGEN turned positive on October 28, 2026. Looking at past instances where CGEN's MACD turned positive, the stock continued to rise in 46 of 49 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CGEN's RSI Oscillator exited the oversold zone, 34 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 66 cases where CGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CGEN as a result. In 71 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
Following a +2.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in 187 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for CGEN moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CGEN entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.092) is normal, around the industry mean (3.498). P/E Ratio (5.158) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.083) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of drug and diagnostics
Industry Biotechnology
Advertisement